title: [Management of patients with castration-resistant metastatic prostate cancer].
abstract: Prostate cancer belongs to the most common malignant tumors in males. Almost in all patients in advanced stage, disease progression occurs despite of castration therapy. Initial treatment of metastatic disease is androgen deprivation therapy. In the case of castration-resistant disease development in asymptomatic patients, it is a combination of abiraterone acetate plus prednisone and in symptomatic patients docetaxel with prednisone are considered gold standards at the present time. The aim of therapy must be assurance of adequate quality of life, pain reduction and survival improvement. The paper presents an overview of current castration-resistant metastatic prostate cancer treatment.
authors.forename: D
authors.initials: D
authors.lastname: Ondruš
authors.forename: M
authors.initials: M
authors.lastname: Ondrušová
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018450:Disease Progression; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009919:Orchiectomy; D064129:Prostatic Neoplasms, Castration-Resistant / Q000556:secondary / Q000628:therapy*
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D005938:Glucocorticoids